Compare Boston Scientific Corporation (BSX) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs H2O America — how do they compare? Boston Scientific Corporation trades at $51.58 (market cap $74.19B), while H2O America trades at $62.42 (market cap $2.61B). The key difference: Boston Scientific Corporation is far larger — about 28.4× H2O America's market cap, and H2O America pays a 2.83% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | HTO | |
|---|---|---|
Market Cap | $74.19B | $2.61B |
Sector | Health | Technology |
52-Week High | $108.14 | $65.43 |
52-Week Low | $42.63 | $44.44 |
Enterprise Value | $86.27B | $4.40B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
HTO trades at $62.42, up 1.92% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a 12.91% net income margin and consistent earnings beats in recent quarters. Recent news highlights transformative acquisitions in Texas, though dilution risks exist. Institutional interest is strong, with Fifth Third Bancorp increasing its stake by 3,753.2% in Q1 2026 (SEC filing, 2026-07-30).
Outlook is positive with an 83.33% analyst buy rating and a consensus price target of $69.50, implying ~11% upside. Risks include execution challenges from acquisitions and potential EPS pressure from equity issuance. The dividend yield remains supported, but growth sustainability depends on operational efficiency amid expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
